ASPEN CIPROFLOXACIN ciprofloxacin injection for intravenous infusion 200mg/100mL bag Australia - English - Department of Health (Therapeutic Goods Administration)

aspen ciprofloxacin ciprofloxacin injection for intravenous infusion 200mg/100ml bag

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

ASPEN CIPROFLOXACIN ciprofloxacin injection for intravenous infusion 100mg/50mL bag Australia - English - Department of Health (Therapeutic Goods Administration)

aspen ciprofloxacin ciprofloxacin injection for intravenous infusion 100mg/50ml bag

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Glucose 50% solution for infusion 50ml vials United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glucose 50% solution for infusion 50ml vials

hameln pharma ltd - glucose anhydrous - solution for infusion - 500mg/1ml

5% Glucose Intravenous Infusion Solution Ireland - English - HPRA (Health Products Regulatory Authority)

5% glucose intravenous infusion solution

maco pharma - glucose monohydrate - solution for infusion - 5 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates

BAXTER 0.15% POTASSIUM CHLORIDE AND 0.225% SODIUM CHLORIDE AND 3.75% GLUCOSE 500mL injection BP Australia - English - Department of Health (Therapeutic Goods Administration)

baxter 0.15% potassium chloride and 0.225% sodium chloride and 3.75% glucose 500ml injection bp

baxter healthcare pty ltd - glucose, quantity: 37.5 g/l; sodium chloride, quantity: 2.25 g/l; potassium chloride, quantity: 1.5 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the potassium chloride ( 0.15%) and sodium chloride (0.225 %) and glucose (3.75 %) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

5% Glucose Intravenous Infusion Solution Ireland - English - HPRA (Health Products Regulatory Authority)

5% glucose intravenous infusion solution

carelide - glucose - solution for infusion - 5 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates

Glucose Intravenous Infusion BP (5% w/v Kenya - English - Pharmacy and Poisons Board

glucose intravenous infusion bp (5% w/v

aculife healthcare pvt ltd commerce house-v, besides vodafone house, prahlad - glucose (as anhyrous) - infusion - each 100 ml contains glucose (as anhydrous) b.p… - other irrigating solutions

Potassium chloride 0.15% (potassium 10mmol/500ml) / Glucose 5% infusion 500ml bags United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium chloride 0.15% (potassium 10mmol/500ml) / glucose 5% infusion 500ml bags

potassium 10mmol/500ml) / glucose 5% infusion 500ml bags (baxter healthcare ltd - glucose anhydrous; potassium chloride - infusion - 50mg/1ml ; 1.5mg/1ml

Potassium chloride 0.3% (potassium 40mmol/1litre) / Glucose 5% infusion 1litre Viaflo bags United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium chloride 0.3% (potassium 40mmol/1litre) / glucose 5% infusion 1litre viaflo bags

potassium 40mmol/1litre) / glucose 5% infusion 1litre viaflo bags (baxter healthcare ltd - glucose anhydrous; potassium chloride - infusion - 50mg/1ml ; 3mg/1ml

D5 INTRAVENOUS INFUSION 500ML Kenya - English - Pharmacy and Poisons Board

d5 intravenous infusion 500ml

amanta healthcare limited c/o surgilinks ltd plot no. 876 national highway no. 8 hariyan- - glucose intravenous infusion bp - infusion - 50gm/l - other i.v. solution additives